Actively Recruiting
Phase IbII Open-Label Study of IN10018 Combined with RNK08954 to Treat KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Led by InxMed (Shanghai) Co., Ltd. · Updated on 2026-02-27
92
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, open-label Phase IbII clinical trial to study the combination of IN10018 and RNK08954 in treating patients with KRASG12D mutation-positive locally advanced or metastatic solid tumors. The study aims to evaluate safety, preliminary efficacy, and determine the best dose of this combination therapy. Pancreatic ductal adenocarcinoma PDAC patients are prioritized, with other tumor types like non-small cell lung cancer NSCLC and colorectal cancer CRC also considered based on early results. The study is divided into two parts Phase Ib focuses on identifying the recommended Phase 2 dose RP2D of IN10018 combined with RNK08954, while Phase II will further assess the treatments anti-tumor effects, safety, and how the drugs behave in the body. Participants will take IN10018 at 100 mg once daily by mouth along with RNK08954 at doses of 1000 mg or 1200 mg once daily until their disease progresses. Participants will be closely monitored through imaging scans like CT or MRI to measure tumor response, and safety evaluations will be conducted regularly over approximately five years. Researchers will assess outcomes such as objective response rate, duration of response, disease control rate, progression-free survival, overall survival, and record any adverse events. The study is led by InxMed Shanghai Co., Ltd.
CONDITIONS
Brief Title
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Research Team
S
Shangyu Chen, Bachelor
L
Lily LI, Bachelor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here